Physician profile
David Wayne Thomas
NPI 1255334405
$6,650.96
in general payments reported to CMS, 2019-2025
37 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $687 · 2021: $1,040 · 2022: $1,115 · 2023: $938 · 2024: $956 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,967 · Education: $14.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,966.84 |
| Education | $14.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $993.93 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $706.78 | 2019-2025 | |
| Astellas Pharma US INC | $637.88 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $549.67 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $507.87 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $312.37 | 2023-2025 | Myfembree, Gemtesa |
| Hologic Sales and Service, LLC | $308.57 | 2020-2025 | Thinprep 2000 Processor, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima |
| Sage Therapeutics, LLC | $283.33 | 2024-2025 | Zurzuvae |
| Exact Sciences Corporation | $278.32 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $257.55 | 2021-2022 | |
| Therapeuticsmd, INC. | $224.20 | 2019-2022 | |
| Organon LLC | $208.18 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $148.52 | 2021 | |
| Gen-Probe Sales & Service, INC. | $140.22 | 2022 | |
| Merck Sharp & Dohme LLC | $139.36 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $135.20 | 2022 | |
| Lupin INC. | $120.75 | 2019-2020 | |
| Biogen, INC. | $119.78 | 2025 | Zurzuvae |
| Glaxosmithkline, LLC. | $65.31 | 2019-2021 | |
| Ethicon US, LLC | $54.78 | 2025 | Vistaseal, Enseal |
| Bayer Healthcare Pharmaceuticals INC. | $53.60 | 2024-2025 | |
| Amag Pharmaceuticals, INC. | $50.56 | 2019 | |
| Agile Therapeutics, INC. | $50.23 | 2021 | |
| Phadia US INC. | $49.88 | 2021 | |
| Avion Pharmaceuticals | $28.29 | 2022 | |
| Convatec INC. | $25.95 | 2019 | |
| Supernus Pharmaceuticals, INC. | $25.64 | 2025 | Qelbree |
| Axonics, INC. | $25.37 | 2022 | |
| Roche Diagnostics Corporation | $19.61 | 2019 | |
| Abbott Laboratories | $19.57 | 2023 | Freestyle Libre 3 |
| Allergan, INC. | $19.48 | 2020 | |
| Baxter Healthcare | $16.64 | 2023 | |
| Olympus America INC. | $16.59 | 2019 | |
| Urovant Sciences INC | $15.79 | 2022 | |
| Acessa Health INC. | $15.30 | 2019 | |
| Smith+Nephew, INC. | $13.19 | 2023 | Pico 7, Pico 14 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.